Tracks brain small vessel disease with genetic and MRI testing
Follows people with small vessel brain disease, using genetic testing and MRI scans.
Plain-language title generated from the registry record
Registry title: Taiwan Associated Genetic and Nongenetic Small Vessel Disease
Key facts
- Where
- Taipei, TaiwanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with signs of cerebral small vessel disease, such as stroke, memory problems, walking problems or brain MRI changes.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- People with at least one sign or history of small vessel disease: stroke, cognitive impairment or dementia, gait disturbance, parkinsonism, headache, family history of hereditary small vessel disease, or small vessel changes on MRI.
- Biomarker or test result
- All participants have gene testing (next-generation sequencing) of five candidate genes. The record does not require a specific result to join.
Main reasons for not taking part
- MRI changes caused by inflammation, cancer or structural lesions
- Patient or family members unwilling to sign informed consent
Read by machine on 9 November 2026.
Where in Taiwan
- Department of Neurology, National Taiwan University HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT05473637
- Record updated
- 20 January 2026
- Original description
The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.Read full original descriptionShow less
Deciphering, Construction and Validation of Magnetic Resonance Imaging Maps, Clinical Features and Outcomes in Genetic and Nongenetic Cerebral Small Vessel Diseases
The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.
Inclusion: Participants must have at least one of the following symptoms/signs or history; stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ICH or young stroke); cognitive impairment or dementia; gait disturbance; parkinsonism (especially vascular parkinsonism features); headache (especially migraine); positive family history of hereditary CSVD; MRI evidence of CSVD (MRI may be done for other reasons), including mild to moderate white matter hyper intensity, any lacune, or any cerebral microbleed.
Exclusion: MRI evidence of CSVD due to other inflammatory, malignancy, or structural lesions; patients or family members not willing to sign informed consent.